James Evans, MD
Neurological Surgery · Wilmington, DENPI 1124048194
Payments from drug & device makers
What this record shows
This record is dominated by royalties or licence payments: $363,324 of the $365,311 with a category attached, or 99.5%. Mizuho America, Inc. accounts for 99.6% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2023 at $136,989 and has fallen 99.9% since, to $117 in 2025.
Across 16 payments — averaging $22,832 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mizuho America, Inc.$364K
- Zap Surgical Systems, Inc.$887
- Zimmer Biomet$140
- Sanofi$133
- Medtronic$117
- Novartis$114
- plus $91 from 2 others
What the payments were for
- Royalty or licence$363,32499%
- Travel & lodging$8870%
- Food & beverage$1,1000%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Mizuho America, Inc. | 8 | $363,830 |
| Zap Surgical Systems, Inc. | 1 | $887 |
| Zimmer Biomet | 1 | $140 |
| Sanofi | 1 | $133 |
| Medtronic | 1 | $117 |
| Novartis | 1 | $114 |
| Johnson & Johnson | 2 | $73 |
| Acclarent, Inc | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few neurological surgery providers in Delawareto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lorazepam | 13 | $16 |
Paid to pharmacies, not to this prescriber.
Other neurological surgery in Wilmington
- Jeffrey CampbellWilmington$63K
- Ashwini SharanWilmington$51K
- Joseph PiattWilmington$137
- Dawn TartaglioneDover$12K
- Tony Anene-MaidohNewark$7K
- Leif-Erik BohmanNewark$5K
- Pawan RastogiNewark$1K
- Kaitlyn MelnickDover$732
- Paul BoulosNewark$504
- Bikash BoseNewark$411
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.